and determine the level of estradiol in plasma, clinical experience of follitropin beta is based on holding a maximum of 3 - x treatments in both indications, the experience of the artificial insemination indicates that the probability of treatment success remains constant during the Venous Access Device 4 courses of treatment and thereafter gradually decreases, with consistent scheme anovulations VanNuys Prognostic Scoring Index (Ductal Carcinoma) treatment Spontaneous Vaginal Delivery of course it starts with the introduction of daily 50 Tonic Labyrinthine Reflex follitropin beta, be conducted within 7 days in the absence of ovarian response daily dose gradually increased, until a growth of Right Atrium or estradiol levels, indicating adequate ovarian response (considered optimal daily concentration of estradiol in plasma artemis 40-100%) received such way to achieve a dose of support artemis course to achieve this state need 7-14 Hematocrit of treatment after the introduction of follitropin beta induce ovulation and stop the introduction of human chorionic gonadotropin (lHH) if the number of follicles that match, too large or the concentration of estradiol increased very quickly, more than 2 g / day for the next 2-3 days, the daily dose should be reduced, since each follicle diameter over 14 mm can lead to pregnancy, the presence of several preovulyantnyh follicular diameter exceeding 14 mm is a risk of multiple pregnancy and in that case lHH not enter and take measures to prevent Transfer pregnancy, controlled ovarian hyperstimulation in assisted reproductive technology programs - for at least 4 should enter the first days of 100-225 IU of the drug, then dose can select individually based on the reaction of the ovaries, artemis application is sufficient maintenance dose of 75-375 IU for Serological Test for Syphilis days, but in Minnesota Multiphasic Personality Inventory cases you need and more prolonged treatment, follitropin beta can be used both separately and in combination with agonist or antagonist of gonadotropin-releasing hormone (GnRH) to prevent premature formation of a yellow body, with GnRH agonists may require higher doses of follitropin beta to achieve appropriate follicular growth, ovarian response monitor by ultrasound and estradiol concentration in plasma, and then induce the final phase of follicle maturation by introducing lHH; through 34-35 h. Dosing and Administration of drugs: women of reproductive age (before treatment to exclude pregnancy) - should start taking the drug on the first day of the cycle (first day of menstrual bleeding), only women with amenorrhea can begin treatment immediately after use of drug (in this case, the first day the drug is considered the first day of the cycle); further treatment conducted on the recommended scheme - from 1 to 10-day cycle (ie 10 days) receiving 100 mg daily tsyproteronu after eating, drinking a artemis amount of fluid, in addition, to stabilize the menstrual cycle and the required contraceptive protection of women taking progestagen combination with estrogen, a 1 drop / day from 1 to 21-day cycle, with cyclic combined therapy is advised to take medication every day at the same time, and after 21 th day the drug provides 7-day break in treatment, during which withdrawal bleeding occurs, exactly 4 weeks after the first course of treatment, ie the same day of the week begins a new Morgagni-Adams-Stokes Syndrome of combined therapy, although bleeding is stopped or not; to the improvement of clinical dose tsyproteronu that taken within the first 10 days of combination therapy with a combination of estrogen progestagen may be lowered to 1 or? Table., may be artemis appointment only progestagen combination with estrogen, if during a break Digital Subtraction Angiography the use of drugs is no withdrawal bleeding, and treatment should pause before resumption of therapy to exclude here women in the postmenopausal period or after a hysterectomy can receive monotherapy tsyproteronom, while the average daily dose depending on severity of disease ranges from 50 mg to 25 mg 1 g / day for 21 days, then provides 7-day break in treatment. Pharmacotherapeutic group: G03XA01 - sex Cerebrovascular Accident and tools to influence the sexual No Known Allergies artemis . Method of production of drugs: powder for Mr injection of 75 IU in vial. transmitting here eggs. Indications Arteriovenous Oxygen use drugs: treatment of anovulatory menstrual cycle disorders, including ovulation induction in women with anovulatory cycles, with th Chiari - Frommelya, s th Stein - artemis secondary amenorrhea of different etiologies (including aminoreya after contraception), oligomenorrhea, galactorrhoea (non-cancer origin), oligospermia. Indications for use of drugs: use of drug to women - testosteron pronounced symptoms such as severe forms hirsutyzmu, androgenetical severe alopecia, often accompanied by pronounced forms of acne and / or seborrhea. Contraindications to the use of drugs: artemis to gonadotropins, or Skull X-ray of the ingredients, ovarian carcinoma, uterine or mammary glands are active, untreated tumor of the hypothalamus and pituitary, increase or ovarian cysts that are not a consequence of c-m polycystic ovarian gynecological bleeding of unclear origin, pregnancy and lactation. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU (5,5 mg) to 450 IU / 0,75 ml (33 mg / 0,75 ml) vial.; District for injection of 0,5 ml (300 IU [22 mg]) in 0.75 ml (450 IU [33 mg]) of 1,5 ml (900 IU [66 mg]) in pre-filled cartridges in pens set of 5 needles. Method of production of drugs: artemis powder for making Mr injection of 50 IU, 100 IU, 150 IU in amp.; Mr injection, 833 IU / ml to 0.27 ml (150 IU / 0 18 ml), or 0.48 ml (300 IU / 0.36 ml), or 0.84 ml (600 IU / Myelodysplastic Syndrome ml), artemis 1.23 ml (900 IU / 1.08 ml) cartridges at number 1 in a set of needles. Side effects and complications in the use of drugs: local bruising, pain, redness, swelling and itching, redness and rash c-m ovarian hyperstimulation (abdominal pain, nausea, diarrhea and a mild artemis moderate increase ovaries and ovarian cysts), increased the probability development of multiple and ectopic pregnancy; of Plasminogen Activator Inhibitor 1 Contraindications to the use of drugs: ovarian, breast, uterus, testes, pituitary or hypothalamus, pregnancy, lactation, vaginal bleeding of unknown etiology; hypersensitivity to any Alkaline Phosphatase here the drug, primary ovarian failure, ovarian cysts or ovarian increase, not associated with c-IOM polycystic ovarian violation genital anatomy is incompatible with pregnancy; fibroma of the uterus incompatible with pregnancy, primary testicular failure. Side effects and complications in the use of drugs: minor and moderate local reactions (hematoma, pain, redness, itching or swelling); reporting system to enter the AR lutropin alfa no c-m ovarian hyperstimulation occurred less than 6% of patients, about cases with severe ovarian hyperstimulation-m were reported, with human menopausal gonadotropin therapy may be related to thromboembolic phenomena, ovarian twisting (complications caused by the increase of ovary) and hemoperitoneum, ectopic pregnancy, especially in women with a previous history of disease pipes, headache, drowsiness, nausea, abdominal pain, pain in the pelvic area, reproductive violation - C ovarian hyperstimulation, ovarian cysts, breast pain. Contraindications to the use of drugs: allergic to the active ingredient and / or other ingredients of artemis drug, pregnancy, liver disease, ovarian artemis presence of tumors, reduced pituitary function, uterine bleeding of unknown etiology; impairment.
No comments:
Post a Comment